Dr. Shah joined Liquidia in May 2020 and oversees all aspects of research, clinical development, medical affairs, and regulatory affairs for the company. Prior to Liquidia, Dr. Shah served as Head of Global Specialty Clinical Development at Teva Pharmaceuticals with oversight of all phases of clinical development across all therapeutic areas including CNS, immunology, respiratory, oncology and biosimilars. Prior to Teva, Dr. Shah served as Senior Vice President, Scientific and Clinical Development at Altana Pharma US, where he built and led their clinical development function, including clinical research and operations, medical affairs, regulatory affairs and quality assurance, pharmacovigilance and drug safety, biostatistics and data management. He began his career at GlaxoSmithKline (GSK), where he held roles of increasing responsibility and most recently served as U.S. Head, Respiratory and Inflammation, Discovery Medicine and Clinical Pharmacology responsible for early-stage clinical development of new therapies for the treatment of chronic obstructive pulmonary disease (COPD), asthma, and rhinitis. Dr. Shah received a M.D. degree from the Hershey Medical College at Pennsylvania State University. He completed his residency in Internal Medicine at the University of North Carolina and fellowship in Allergy, Asthma and Clinical Immunology at Johns Hopkins University.